The REPROCELL Blog

Press Release: ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

[fa icon="calendar'] Oct 10, 2018 6:35:50 AM / by Simon Padbury posted in Press Release, Research & Development, iPSCs, Stem Cells, Clinical Grade

[fa icon="comment"] 0 Comments

Funding will be used to improve efficiency of induced pluripotent stem cell production

Location: REPROCELL Europe Ltd. (Glasgow, UK) and  RosslinCT (Edinburgh, UK)
Date: October 10, 2018
Continue reading [fa icon="long-arrow-right"]

From Frying-Pan to Fire

[fa icon="calendar'] Sep 13, 2018 7:54:45 AM / by Zara Puckrin posted in Research & Development, Government Partnership, Internship

[fa icon="comment"] 0 Comments

How can industry inspire the next generation of life science professionals?  Summer intern Zara Puckrin describes the challenges faced by today’s graduates and explains how REPROCELL have helped her to bridge the gap between university and work.

Continue reading [fa icon="long-arrow-right"]

The Human Touch: meeting clinical needs in IBD research

[fa icon="calendar'] Sep 7, 2018 6:05:47 AM / by Zara Puckrin posted in Drug Discovery, Human Tissues, Inflammatory Bowel Disease

[fa icon="comment"] 0 Comments

There is a clinical need for novel therapies in Inflammatory Bowel Disease. Current research is however limited by models which do not physiologically mimic the disease in humans. REPROCELL’s Human IBD Fresh Tissue Assay is the most clinically relevant IBD model on the market and the only commercially available assay of its kind.

Continue reading [fa icon="long-arrow-right"]

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

[fa icon="calendar'] Jun 26, 2018 5:46:01 AM / by Dr David Bunton posted in Human Tissues, Ussing Chambers

[fa icon="comment"] 0 Comments

A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.

Continue reading [fa icon="long-arrow-right"]

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

[fa icon="calendar'] Jun 21, 2018 8:44:03 AM / by Chirag Tawde posted in Human Tissues, Drug Discovery, primary cells

[fa icon="comment"] 0 Comments

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

Continue reading [fa icon="long-arrow-right"]

Join REPROCELL at ISSCR 2018 in Melbourne, Australia

[fa icon="calendar'] Jun 15, 2018 8:07:06 AM / by Robert Annand posted in Stem Cells, ISSCR

[fa icon="comment"] 0 Comments

ISSCR (the International Society for Stem Cell Research) is the preeminent stem cell research group in the world. ISSCR is holding its 2018 Annual Meeting in Melbourne, Australia – and REPROCELL will be there.

Join us 20-23 June at booth 74 and learn how we can help you with your stem cell needs.

Continue reading [fa icon="long-arrow-right"]

REPROCELL's footprint extends to serve life sciences in India

[fa icon="calendar'] Jun 13, 2018 11:07:41 AM / by Rama Modali posted in Stem Cells, Human Tissues, Bioinformatics, Genome Sequencing, Global Expertise

[fa icon="comment"] 0 Comments

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.

Continue reading [fa icon="long-arrow-right"]

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

[fa icon="calendar'] May 25, 2018 11:03:43 AM / by Dr David Bunton

[fa icon="comment"] 0 Comments

The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.

Continue reading [fa icon="long-arrow-right"]

Factors to consider when planning a iPSC reprogramming project

[fa icon="calendar'] May 18, 2018 8:03:40 AM / by Dr Sarah Eminli-Meissner

[fa icon="comment"] 0 Comments

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.

Continue reading [fa icon="long-arrow-right"]

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

[fa icon="calendar'] Apr 18, 2018 4:44:17 AM / by Simon Padbury

[fa icon="comment"] 0 Comments

REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's  trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.

Continue reading [fa icon="long-arrow-right"]